Author information
1Department of Biobehavioral Nursing and Health Informatics, University of Washington, Box 357260, Seattle, Washington, 98195, USA. paulac@uw.edu.
2Department of Child, Family, and Population Health Nursing, University of Washington, Box 357260, Seattle, Washington, 98195, USA.
3Department of Health, Washington State, Tumwater, Washington, USA.
4Washington State Office of Financial Management, Olympia, WA, USA.
5Washington State Health Care Authority, Olympia, WA, USA.
6Office of Nursing Research, University of Washington, Box 357260, Seattle, Washington, 98195, USA.
7Department of Pharmacy, University of Washington, Box 357630, Seattle, Washington, 98195, USA.
8Department of Global Health, University of Washington, Box 351620, Seattle, Washington, 98195, USA.
Abstract
Background: Despite curative treatment options since 2014, only 12% of individuals in Washington State diagnosed with Hepatitis C (HCV) received treatment in 2018. Washington State agencies launched an elimination plan in 2019 to promote access to and delivery of HCV screening and treatment. The purpose of this study is to evaluate provider and health system barriers to successful implementation of HCV screening and treatment across Washington State.
Methods: This is a cross-sectional online survey of 547 physicians, nurse practitioners, physician assistants, and clinical pharmacists who provide care to adult patients in Washington State conducted in 2022. Providers were eligible if they worked in a primary care, infectious disease, gastroenterology, or community health settings. Questions assessed HCV screening and treating practices, implementation barriers, provider knowledge, observed stigma, and willingness to co-manage HCV and substance use disorder. Chi-squared or fishers exact tests compared characteristics of those who did and did not screen or treat.
Results: Provider adoption of screening for HCV was high across the state (96%), with minimal barriers identified. Fewer providers reported treating HCV themselves (28%); most (71%) referred their patients to another provider. Barriers identified by those not treating HCV included knowledge deficit (64%) and lack of organizational support (24%). The barrier most identified in those treating HCV was a lack of treating clinicians (18%). There were few (< 10%) reports of observed stigma in settings of HCV treatment. Most clinicians (95%) were willing to prescribe medication for substance use disorders to those that were using drugs including alcohol.
Conclusion: Despite widespread screening efforts, there remain barriers to implementing HCV treatment in Washington State. Lack of treating clinicians and clinician knowledge deficit were the most frequently identified barriers to treating HCV. To achieve elimination of HCV by 2030, there is a need to grow and educate the clinician workforce treating HCV.